Clinical Trials
25 trialsNCT01272037 2026-05-26
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06075953 2026-05-22
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06195306 2026-05-20
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05941520 2026-05-13
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06184750 2026-05-13
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT06982313 2026-03-11
Babytam long
Ente Ospedaliero Ospedali Galliera
Completed
NCT06033092 2025-08-28
TOLERANT
European Institute of Oncology
Phase 2 Active not recruiting
NCT02993159 2024-12-18
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Northwestern University
Phase 2 Completed
NCT00072462 2024-09-19
IBIS-II DCIS
Queen Mary University of London
Phase 3 Completed
NCT01357772 2023-07-17
TAM-01
Ente Ospedaliero Ospedali Galliera
Phase 3 Active not recruiting
NCT00003857 2022-05-25
Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04666961 2022-04-22
HORNEO01
Institut Cancerologie de l'Ouest
Phase 2 Recruiting
NCT00290745 2020-12-04
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
University of California, San Francisco
Phase 1/2 Completed
NCT04046159 2019-08-06
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
National Taiwan University Hospital
Phase 3 Unknown
NCT00053898 2018-09-20
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
NSABP Foundation Inc
Phase 3 Completed
NCT00290654 2017-12-28
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00764322 2017-08-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00005886 2017-01-13
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
University of Kansas Medical Center
Phase 1 Completed
NCT00031720 2016-07-13
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01293032 2016-07-12
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
Virginia Commonwealth University
Phase NA Completed
NCT00952731 2015-07-21
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Northwestern University
Phase 2 Completed
NCT00126464 2013-11-06
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
National Cancer Institute (NCI)
Phase NA Unknown
NCT00002920 2012-10-31
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00077168 2009-02-09
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
National Cancer Institute (NCI)
Phase 2 Unknown